Benten Biotech specializes in the development and application of recombinant single-domain antibodies (VHH), which represent a novel approach in antibody engineering. These antibodies have demonstrated efficacy in both therapeutic and diagnostic contexts, as evidenced by their use in clinical trials. The company offers high-throughput discovery services for VHH antibodies, focusing on enhancing reproducibility, specificity, and robustness in research and development. Additionally, Benten Biotech is involved in the maturation of antibody affinity, target selection, and the design and validation of diagnostic kits, which are crucial for various applications in both human and veterinary medicine.

In the veterinary sector, Benten Biotech provides a range of biotechnological solutions, including standardized antigens and antibodies, as well as vaccine antigen quantification kits. Their services extend to outsourced control of vaccine potency, adhering to stringent standards set by the European Pharmacopoeia and U.S. regulations. The company is also engaged in the development of custom kits for antigen quantification and the estimation of vaccine potency, alongside consultancy services for the production and quality control of veterinary vaccines. Through these initiatives, Benten Biotech aims to enhance the quality and efficacy of veterinary biologics, contributing significantly to the field of veterinary medicine.

Uruguay

BENTEN BIOTECH is committed to strengthening the R&D+i capabilities of the global animal vaccines laboratories.

BIOTECH BENTEN designs new products and optimizes processes to ensure effectiveness and quality of final products under quality standards of US and EU pharmacopoeia, covering the specific R&D+i needs of the veterinary industry.

Benten Biotech

Company Details